Close menu

July 7th, 2022 | 14:33 CEST

A big surprise at BioNTech, and what are Valneva and NervGen doing?

  • Biotechnology
  • research
Photo credits:

Surprise at BioNTech: competitor CureVac sues the Mainz-based biotech company for alleged patent infringements. Specifically, the lawsuit concerns BioNTech's Corona vaccine, which is based on mRNA technology. CureVac founder Ingmar Hoerr, in turn, is considered the discoverer of this new vaccination technology. However, CureVac failed with the development of its own Corona vaccine. Valneva also had no luck with its Corona vaccine, but it seems to have an attractive product pipeline. Nevertheless, the euphoria over the entry of the US pharmaceutical group Pfizer has faded. The situation at NervGen is different: according to experts, NervGen could achieve its greatest success in decades with NVG-291 in the fight against Alzheimer's disease. Tomorrow, a capital increase is to be completed, and the share price will likely regain momentum.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , VALNEVA SE EO -_15 | FR0004056851 , NERVGEN PHARMA CORP | CA64082X2032

Table of contents:

    NervGen: Will the breakthrough in the fight against Alzheimer's succeed?

    It sounds exciting: Treating nerve damage in various diseases such as spinal cord injuries, multiple sclerosis or Alzheimer's disease with a single drug - this is the goal of NervGen Pharma. To this end, the Canadian company is currently developing the compound NVG-291 and recently received approval to administer the third and highest dose in the clinical trial. As a result, this will allow Phase 1b/2a to start in the second half of the year for efficacy in patients with Alzheimer's disease and spinal cord injury. The Phase 2 trial in patients with multiple sclerosis is expected to start in early 2023. A corporate action with gross proceeds of approximately USD 15 million is currently underway for financing. The share price could gain new momentum if it is completed tomorrow as planned. NervGen's planned IPO on NASDAQ should also contribute to this, with the IPO expected to take place before the end of the year.

    By way of background, existing drugs have so far only been able to limit or contain the extent of nerve damage. In the case of Alzheimer's disease, existing drug therapies can only slightly slow down the progression of the disease. That is no consolation either for those affected or for their relatives. Experts believe that with NVG-291, NervGen could achieve its greatest success in decades in the fight against Alzheimer's disease. The potential is correspondingly enormous. In the US alone, there are about 6 million cases of Alzheimer's disease and, in addition, 900,000 patients with multiple sclerosis and 300,000 chronic patients with spinal cord injuries. What these diseases all have in common is that nerves are damaged and the body responds by scarring to contain the damage. However, scarring inhibits the body's ability to regrow and regenerate the central nervous system. If the upcoming trial results for NVG-291 are successful, the chances are good that NervGen shares will no longer trade below their high for the year at EUR 1.87. Currently, the share is trading at around EUR 1.44.

    BioNTech: CureVac lawsuit settled?

    Probably only very few had expected this - CureVac, which failed with its Corona vaccine, is suing BioNTech. A lawsuit has been filed with the Düsseldorf Regional Court for patent infringement. The case concerns the mRNA technology and thus BioNTech's Corona vaccine Comirnaty. From CureVac's point of view, BioNTech has infringed several patents, for example, in the production of mRNA molecules. CureVac is therefore demanding appropriate compensation for an infringement of intellectual property rights. BioNTech rejected the accusations. The Mainz-based biotech company said it respects valid intellectual property rights. BioNTech's work is "original," and it will defend it vigorously against any allegations of patent infringement. It is not uncommon, he said, for other pharmaceutical companies to now claim that the vaccine potentially infringes on their intellectual property rights in the wake of the BioNTech vaccine's success. Analysts have not yet commented on the dispute. Most recently, BioNTech had given an update on its ongoing development work at a virtual conference. As a result, Deutsche Bank confirmed its price target of USD 180 for the BioNTech share. It is currently trading at around USD 150. At the event, BioNTech presented a vision for a time after the Corona pandemic. In this context, the oncology segment looks promising, the analysts said.

    Valneva: Euphoria gone?

    Valneva shareholders currently need strong nerves. After the share had doubled in June, it went down again strongly in recent days. Initially, a deal with Pfizer had electrified investors. Specifically, the agreement provides for the US pharmaceutical group to take an 8% stake in Valneva and pay around EUR 90.5 million for it. Milestone payments have also been agreed upon. The entry is due to the Lyme disease vaccine candidate with blockbuster potential. Valneva plans to start the Phase 3 trial in the third quarter of 2022. Subsequently, the share price doubled to almost EUR 15 within a few days. But then disillusionment set in. By the beginning of July, the share had briefly fallen below the EUR 10 mark. It is currently trading at EUR 11, meaning the chart is clearly weakened again. It cannot be ruled out that the share will test the old lows between EUR 7 and 8 in a weak market environment. Positive operating news for a sustained share price recovery is currently not foreseeable.

    Biotech investors traditionally need strong nerves and patience. The stock market is currently taking a relaxed view of the CureVac lawsuit, and analysts have not yet changed their opinion of BioNTech. NervGen could face an exciting second half of the year after the successful completion of the capital measure. At Valneva, the air seems to be out again for the time being.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

    Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Pharma

    High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!


    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.


    Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST

    Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys

    • AI
    • Biotechnology
    • Investments

    The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and However, the biotech sector has recently started to climb again. Where are the opportunities for investors?